Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Iyer, Chitraa; 1 | Wang, Xueqiana; 1 | Renusch, Samantha R.a | Duque, Sandra I.a | Wehr, Allison M.b | Mo, Xiaokui-Mollyb | McGovern, Vicki L.a | Arnold, W. Davidc; d | Burghes, Arthur H.M.a | Kolb, Stephen J.a; c; *
Affiliations: [a] Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, Oh, USA | [b] Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Oh, USA | [c] Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Oh, USA | [d] Department of Physical Medicine and Rehabilitation, The Ohio State University Wexner Medical Center, Columbus, Oh, USA
Correspondence: [*] Correspondence to: Stephen J. Kolb, M.D., Ph.D., Associate Professor, Department of Neurology, Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Rightmire Hall, Rm 226A, 1060 Carmack Road, Columbus, OH 43214, USA. E-mail: stephen.kolb@osumc.edu.
Note: [1] Each author contributed equally to all aspects of this work.
Abstract: Background: Spinal Muscular Atrophy (SMA) is an autosomal recessive motor neuron disease that results in loss of spinal motor neurons, muscular weakness and, in severe cases, respiratory failure and death. SMA is caused by a deletion or mutation of the SMN1 gene and retention of the SMN2 gene that leads to low SMN expression levels. The measurement of SMN mRNA levels in peripheral blood samples has been used in SMA clinical studies as a pharmacodynamic biomarker for response to therapies designed to increase SMN levels. We recently developed a postnatal porcine model of SMA by the viral delivery of a short-hairpin RNA (shRNA) targeting porcine SMN (pSMN). scAAV9-mediated knockdown of pSMN mRNA at postnatal day 5 results in denervation, weakness and motor neuron and ventral root axon loss that begins 3-4 weeks after viral delivery, and this phenotype can be ameliorated by subsequent viral delivery of human SMN (hSMN). Objective: To determine if the effect of modulating SMN levels using gene therapy can be measured in blood. Methods: We measured expression of pSMN mRNA and hSMN mRNA by quantitative droplet digital PCR (ddPCR). Results: We found that the endogenous expression of pSMN mRNA in blood increases in the first month of life. However, there were no significant differences in blood levels of pSMN mRNA after knock-down or of human SMN mRNA after gene therapy. Conclusions: Our results, obtained in a large animal model of SMA that is similar in size and anatomy to human infants, suggest that measurement of SMN mRNA levels in blood may not be informative in SMA clinical trials involving intrathecal delivery of SMN-modulating therapies.
Keywords: ddPCR, gene-therapy, scAAV9-shRNA, scAAV9-SMN, SMA, SMN
DOI: 10.3233/JND-170209
Journal: Journal of Neuromuscular Diseases, vol. 4, no. 1, pp. 59-66, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl